zovirax suspension 200 mg5 ml
glaxosmithkline pte ltd - acyclovir - suspension - 200 mg/5 ml - acyclovir 200 mg/5 ml
seroxat oral suspension 20 mg/ml
ltt pharma limited - paroxetine hydrochloride - oral suspension - 20 mg/ml
seroxat 20 mg/ml oral suspension
ltt pharma limited - paroxetine hydrochloride - oral suspension - 20 mg/ml
tribamec duo 50 mg/ml & 1 mg/ml oral suspension for sheep
eu pharmaceuticals ltd - ivermectin, triclabendazole - oral suspension - endectocide - sheep
pyrocam 15 mg/ml oral suspension for pigs
huvepharma n.v. - meloxicam - oral suspension - anti inflammatory nsaid - pigs
seroxat 20mg/10ml liquid
glaxosmithkline uk ltd - paroxetine hydrochloride - oral suspension - 2mg/1ml
parafen suspension suspension and effervescent granules for oral
sphinx pharmaceuticals ltd 69512-00400 - ibuprofen paracetamol - suspension and effervescent granules for oral - ibuprofen 100mg/5ml paracetamol120mg/5ml - non-opioid analgesics andantipyretics: anilides
tystatin oral suspension
imeks pharma sdn. bhd. - nystatin -
motidom oral suspension 1mgml
imeks pharma sdn. bhd. - domperidone -
versacloz
douglas pharmaceuticals limited - clozapine 50 mg/ml - oral suspension - 50 mg/ml - active: clozapine 50 mg/ml excipient: glycerol hydrochloric acid monobasic sodium phosphate dihydrate povidone sodium hydroxide sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate sorbitol water xanthan gum - indicated in the treatment of resistant schizophrenic patients only (i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics). non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).